Efficacy criteria and cholesterol targets for LDL apheresis

Atherosclerosis

Volumn 208, Issue 2, 2010, Pages 317-321

  Thompson, Gilbert R ^a   Barbir, M ^b   Davies, D ^c   Dobral, P ^c   Gesinde, M ^d   Livingston, M ^c   Mandry, P ^c   Marais, A D ^e   Matthews, S ^f   Neuwirth, C ^a   Pottle, A ^b   le Roux, C ^a   Scullard, D ^c   Tyler, C ^c   Watkins, S ^f  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

^b HAREFIELD HOSPITAL   (United Kingdom)

^c HEART UK ^*  (United Kingdom)

^d Leeds Blood Centre   (United Kingdom)

^e UNIVERSITY OF CAPE TOWN   (South Africa)

^f LLANDOUGH HOSPITAL   (United Kingdom)

Author keywords

Cardiovascular disease monitoring; Familial hypercholesterolaemia; LDL kinetics

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

APHERESIS; BLOOD VOLUME; CATABOLISM; CHOLESTEROL BLOOD LEVEL; DRUG MEGADOSE; DRUG TARGETING; FAMILIAL HYPERCHOLESTEROLEMIA; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; PLASMAPHERESIS; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; BLOOD COMPONENT REMOVAL; CARDIOVASCULAR DISEASES; CHILD; CHOLESTEROL, LDL; HETEROZYGOTE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; KINETICS; LIPIDS; LIPOPROTEINS, LDL; REPRODUCIBILITY OF RESULTS; TIME FACTORS;

EID: 74749107585     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.06.010     Document Type: Review

References (29)

1. National Institute for Health and Clinical Excellence. Identification and management of familial hypercholesterolaemia. NICE clinical guideline 71; August 2008.
2. Thompson G.R., Barbir M., Davies D., et al. Recommendations for the use of LDL apheresis. Atherosclerosis 198 (2008) 247-255
3. Schettler V., Wieland E., Armstrong V.W., et al. First steps toward the establishment of a German low-density lipoprotein-apheresis registry: recommendations for the indication and for quality management. Ther Apher 6 (2002) 381-383
4. Szczepiorkowski Z.M., Bandarenko M., Kim H.C., et al. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the apheresis applications committee of the American society for apheresis. J Clin Apher 22 (2007) 106-175
5. Palcoux J.-B., Atassi-Dumont M., Lefevre P., et al. Low-density lipoprotein apheresis in children with familial hypercholesterolemia: follow-up to 21 years. Ther Apher Dial 12 (2008) 195-201
6. Hudgins L., Kleimann B., Scheuer A., White S., and Gordon B.R. Long-term safety and efficacy of low-density lipoprotein apheresis in childhood for homozygous familial hypercholesterolemia. Am J Cardiol 102 (2008) 1199-1204
7. Kolansky D.M., Cuchel M., Clark B.J., et al. Longitudinal evaluation and assessment of cardiovascular disease in patients with homozygous familial hypercholesterolemia. Am J Cardiol 102 (2008) 1438-1443
8. Hoeg J.M., Feuerstein I.M., and Tucker E.E. Detection and quantitation of calcific atherosclerosis by ultrafast computed tomography in children and young adults with homozygous familial hypercholesterolemia. Arterioscler Thromb 14 (1994) 1066-1074
9. Sidhu P.S., Naoumova R.P., Maher V.M., et al. The extracranial carotid artery in familial hypercholesterolaemia: relationship of intimal-medial thickness and plaque morphology with plasma lipids and coronary heart disease. J Cardiovasc Risk 3 (1996) 61-67
10. Arends J., Bier D.M., Schafer G., et al. No evidence for feedback inhibition of hepatic apolipoprotein B (apoB) production after extracorporeal low density lipoprotein precipitation as determined by [1-13C] leucine infusion in normal volunteers. Eur J Clin Invest 23 (1993) 602-614
11. Thompson G.R., Spinks T., Ranicar A., and Myant N.B. Non-steady state studies of low-density-lipoprotein turnover in familial hypercholesterolaemia. Clin Sci Mol Med 52 (1977) 361-369
12. Parhofer K.G., Barrett P.H., Demant T., and Schwandt P. Acute effects of low density lipoprotein apheresis on metabolic parameters of apoliprotein B. J Lipid Res 41 (2000) 1596-1603
13. Marais A.D., Naoumova R.P., Firth J.C., Penny C., Neuwirth C.K., and Thompson G.R. Decreased production of low density lipoprotein by atorvastatin after apheresis in homozygous familial hypercholesterolemia. J Lipid Res 38 (1997) 2071-2078
14. Pfohl M., Naoumova R.P., Klass C., et al. Acute and chronic effects on cholesterol biosynthesis of LDL-apheresis with or without concomitant HMG-CoA reductase inhibitor therapy. J Lipid Res 35 (1994) 1946-1955
15. Bilheimer D.W., Grundy S.M., Brown M.S., and Goldstein J.L. Mevinolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 80 (1983) 4124-4128
16. Kroon A.A., van't Hof M.A., Demacker P.N., and Stalenhoef A.F. The rebound of lipoproteins after LDL-apheresis. Kinetics and estimation of mean lipoprotein levels. Atherosclerosis 152 (2000) 519-526
17. Thompson G.R., Maher V.M., Matthews S., et al. Familial hypercholesterolaemia regression study: a randomised trial of low-density-lipoprotein apheresis. Lancet 345 (1995) 811-816
18. Thompson G.R. Plasma exchange for hypercholesterolaemia. Lancet 1 (1981) 1246-1248
19. Scharnagl H., Nauck M., Wieland H., and März W. The Friedewald formula underestimates LDL cholesterol at low concentrations. Clin Chem Lab Med 39 (2001) 426-431
20. Gagné C., Gaudet D., Bruckert E., et al. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation 105 (2002) 2469-2475
21. Civiera F. For International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis 173 (2004) 55-68
22. Jaeger B., Richter Y., Nagel D., et al. Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events. Nat Clin Pract Cardiovasc Med 6 (2009) 229-239
23. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 44 (2004) 720-732
24. Webb J.C., Sun X.M., McCarthy S.M., et al. Characterization of mutations in the low density lipoprotein (LDL)-receptor gene in patients with homozygous familial hypercholesterolemia, and frequency of these mutations in FH patients in the United Kingdom. J Lipid Res 37 (1996) 368-381
25. Rallidis L., Naoumova R.P., Thompson G.R., and Nihoyannopoulos P. Extent and severity of atherosclerotic involvement of the aortic valve and root in familial hypercholesterolaemia. Heart 80 (1998) 583-590
26. Marais A.D., Firth J.C., Rose A.G., and Berger G.M. Fatal outcome of homozygous familial hypercholesterolaemia in a black patient. A case report. S Afr Med J 77 (1990) 588-590
27. Descamps O.S., Gilbeau J.P., Luwaert R., and Heller F.R. Impact of genetic defects on coronary atherosclerosis in patients suspected of having familial hypercholesterolaemia. Eur J Clin Invest 33 (2003) 1-9
28. Cuchel M., Bloedon L.T., Szapary P.O., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Eng J Med 356 (2007) 148-156
29. Kastelein J.P., Akdim F., Trip M.D., et al. ISIS.301012, an antisense inhibitor of apoB, produces significant additional reduction of LDL-C and apoB in hypercholesterolemic subjects on statins not meeting target. Atheroscler Suppl 8-1 (2007) 198-199